We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 28% below its sector, cheaper than its peers on earnings.
Emmessar Biotech & Nutrition Ltd. specializes in the creation and distribution of health-related and dietary products. The company's operations are segmented into Healthcare, Fine Chemicals, and income generated from leased property. Its product offerings encompass solutions for dermatological care, general wellness, musculoskeletal support, pain management, and sexual health. Established by Mathurakavi Srinivas Raghavan Ayyangar on March 17, 1992, the firm is headquartered in Mumbai, India.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save EMMESSA.BO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
